"Presumably, the pushback in the past was due to lack of financing? Well now with the $30M secured loan and the preliminary short form prospectus (proposed offering of units) both trials will go ahead this time around."

Using the term "will" is suggesting a 100% probability. There are lots of things that may happen between now and the potential start of either trial. As of right now, the probability of one or both trials (renal, Fabry) starting would seem greater than the probability of them being withdrawn. The October revised estimated start date of Fabry trial is 3 months further out than the July revised estimated start date of renal trial. With the SSRA still pending and the potential for expanding/lengthening BoM as a result of the SSRA, I give the renal trial a 50/50 chance of being delayed again. I'm not even going to mention the other possibility that may happen with a BoM DSMB/SSRA/futility analysis (oops did I just give that away?). Funds from loan/proposed offering may need to be used for BoM (as planned, and especially if expanded/lengthened) instead of renal/Fabry. The loan/proposed offerings haven't closed yet, and the TSX review is still pending. So don't count your chicks before those eggs crack. Once the dominoes start falling, probabilities will change. All just my opinion. DYODD.